Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$76.72 USD
+0.82 (1.08%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $76.71 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Cash flow Statements
Fiscal Year End for Gilead Sciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 5,613.00 | 4,566.00 | 6,201.00 | 89.00 | 5,364.00 |
Depreciation/Amortization & Depletion | 2,693.00 | 2,103.00 | 2,050.00 | 1,480.00 | 1,404.00 |
Net Change from Assets/Liabilities | -2,303.00 | -1,763.00 | 489.00 | -1,638.00 | -798.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2,002.00 | 4,166.00 | 2,644.00 | 8,237.00 | 3,174.00 |
Net Cash From Operating Activities | 8,006.00 | 9,072.00 | 11,384.00 | 8,168.00 | 9,144.00 |
Property & Equipment | -585.00 | -728.00 | -579.00 | -650.00 | -825.00 |
Acquisition/ Disposition of Subsidiaries | -1,152.00 | -1,797.00 | -1,402.00 | -25,742.00 | 0.00 |
Investments | -528.00 | 60.00 | -987.00 | 11,948.00 | -2,307.00 |
Other Investing Activities | -1.00 | -1.00 | -163.00 | -171.00 | -4,685.00 |
Net Cash from Investing Activities | -2,265.00 | -2,466.00 | -3,131.00 | -14,615.00 | -7,817.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -768.00 | -1,087.00 | -377.00 | -1,327.00 | -1,540.00 |
Issuance (Repayment) of Debt | -270.00 | -1,500.00 | -4,750.00 | 5,684.00 | -2,750.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -3,809.00 | -3,709.00 | -3,605.00 | -3,449.00 | -3,222.00 |
Other Financing Activities | -279.00 | -173.00 | -145.00 | -138.00 | -122.00 |
Net Cash from Financing Activities | -5,125.00 | -6,469.00 | -8,877.00 | 770.00 | -7,634.00 |
Effect of Exchange Rate Changes | 57.00 | -63.00 | -35.00 | 43.00 | -2.00 |
Net Change In Cash & Equivalents | 673.00 | 74.00 | -659.00 | -5,634.00 | -6,309.00 |
Cash at Beginning of Period | 5,412.00 | 5,338.00 | 5,997.00 | 11,631.00 | 17,940.00 |
Cash at End of Period | 6,085.00 | 5,412.00 | 5,338.00 | 5,997.00 | 11,631.00 |
Diluted Net EPS | 4.50 | 3.64 | 4.93 | 0.10 | 4.22 |
Fiscal Year End for Gilead Sciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -2,556.00 | -4,170.00 | 5,613.00 | 4,196.00 | 2,024.00 |
Depreciation/Amortization & Depletion | 1,384.00 | 690.00 | 2,693.00 | 2,005.00 | 1,321.00 |
Net Change from Assets/Liabilities | -2,005.00 | -459.00 | -2,303.00 | -1,760.00 | -211.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6,720.00 | 6,158.00 | 2,002.00 | 1,397.00 | 948.00 |
Net Cash From Operating Activities | 3,544.00 | 2,219.00 | 8,006.00 | 5,837.00 | 4,082.00 |
Property & Equipment | -235.00 | -105.00 | -585.00 | -370.00 | -248.00 |
Acquisition/ Disposition of Subsidiaries | -4,195.00 | -4,043.00 | -1,152.00 | -873.00 | -794.00 |
Investments | 1,904.00 | 1,938.00 | -528.00 | -295.00 | -261.00 |
Other Investing Activities | 12.00 | 5.00 | -1.00 | 0.00 | -6.00 |
Net Cash from Investing Activities | -2,514.00 | -2,207.00 | -2,265.00 | -1,538.00 | -1,309.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -349.00 | -254.00 | -768.00 | -644.00 | -427.00 |
Issuance (Repayment) of Debt | -1,851.00 | 0.00 | -270.00 | -271.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -1,962.00 | -990.00 | -3,809.00 | -2,866.00 | -1,913.00 |
Other Financing Activities | -152.00 | -116.00 | -279.00 | -245.00 | -167.00 |
Net Cash from Financing Activities | -4,314.00 | -1,361.00 | -5,125.00 | -4,026.00 | -2,507.00 |
Effect of Exchange Rate Changes | -29.00 | -18.00 | 57.00 | 20.00 | 26.00 |
Net Change In Cash & Equivalents | -3,313.00 | -1,367.00 | 673.00 | 293.00 | 292.00 |
Cash at Beginning of Period | 6,085.00 | 6,085.00 | 5,412.00 | 5,412.00 | 5,412.00 |
Cash at End of Period | 2,772.00 | 4,718.00 | 6,085.00 | 5,705.00 | 5,704.00 |
Diluted Net EPS | 1.29 | -3.34 | 1.14 | 1.73 | 0.83 |